Literature DB >> 25243936

Chemotherapy parity laws: a remedy for high drug costs?

Bo Wang1, Steven Joffe2, Aaron S Kesselheim1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25243936     DOI： 10.1001/jamainternmed.2014.4878

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  6 in total

1.  Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.

Authors:  Stacie B Dusetzina; Haiden A Huskamp; Aaron N Winn; Ethan Basch; Nancy L Keating
Journal:  JAMA Oncol       Date:  2018-06-14       Impact factor: 31.777

2.  Use of Charity Financial Assistance for Novel Oral Anticancer Agents.

Authors:  Adam J Olszewski; Andrew R Zullo; Christopher R Nering; Justin P Huynh
Journal:  J Oncol Pract       Date:  2018-02-13       Impact factor: 3.840

3.  Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers.

Authors:  Stacie B Dusetzina; Haiden A Huskamp; Shelley A Jazowski; Aaron N Winn; William A Wood; Adam Olszewski; Ethan Basch; Nancy L Keating
Journal:  J Natl Cancer Inst       Date:  2020-10-01       Impact factor: 13.506

4.  Adherence to Oral Anticancer Medications: Evolving Interprofessional Roles and Pharmacist Workforce Considerations.

Authors:  Gennaro A Paolella; Andrew D Boyd; Scott M Wirth; Sandra Cuellar; Neeta K Venepalli; Stephanie Y Crawford
Journal:  Pharmacy (Basel)       Date:  2018-03-08

5.  Why individual-level interventions are not enough: Systems-level determinants of oral anticancer medication adherence.

Authors:  Lorraine T Dean; Marshalee George; Kimberley T Lee; Kimlin Ashing
Journal:  Cancer       Date:  2020-05-21       Impact factor: 6.860

6.  Patient recommendations for reducing long-lasting economic burden after breast cancer.

Authors:  Lorraine T Dean; Shadiya L Moss; Sarah I Rollinson; Livia Frasso Jaramillo; Raheem J Paxton; Jill T Owczarzak
Journal:  Cancer       Date:  2019-03-06       Impact factor: 6.860
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.